You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202271 - 202280 of 207725 results
  1. Device for overground gait/balance training post-stroke

    SBC: CHICAGO PT, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Chicago PT is developing rehabilitation robotics to help clinicians provide more intensive functional retraining of overground walking, post-stroke. Chicago PT's concept is to build devices that work with the clinician rather than replacing the clinician, in order to retain the clinician's skilled manual connection with the patient in all its important aspects: ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  2. Neural cell based assays derived from human ES cells

    SBC: ARUNA BIO, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Neurons send instructions to other cells in the form of electrical signals that allow movement, sensation, memory, learning and countless other activities that are taken for granted in daily life. Loss of neural cell function results from traumatic injuries such as gunshots wounds or car accidents and from neurodegenerative diseases. The scale of this health p ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  3. Therapeutic Strategy for Recurrent Spontaneous Abortion

    SBC: Nora, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Recurrent spontaneous abortion (RSA) is a serious medical condition that affects approximately 1-3% of reproductive age women. At present, there is no FDA approved treatment for RSA. We hypothesize that failure to suppress Th1 cytokine production early in pregnancy is a major cause of RSA. We hypothesize that recombinant human granulocyte colony stimulating fa ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  4. The Quintessential Ventricular Cannula

    SBC: LAUNCHPOINT TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Chronic mechanical circulatory support has been progressively migrating towards the use of turbo-dynamic blood pumps. For many reasons, these "second-" and "third-generation" devices offer advantages over the current pulsatile generation of ventricular assist devices. However, ventricular unloading with dynamic blood pumps can be markedly affected by the geomet ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  5. ESA, a Novel Anti-inflammation Agent

    SBC: EVA PHARMACEUTICAL, LLC.            Topic: N/A

    DESCRIPTION (provided by applicant): We have discovered that Esculentoside A (EsA) has potent anti-inflammatory effects including specific COX2 inhibition. Our preliminary studies and the associated patent apply to the use of EsA for the prevention of radiation-related inflammation (IR). We found that EsA was more effective than Celebrex at preventing and reducing acute radiation dermatitis and l ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Oral Therapeutic for Beta-Thalassemia

    SBC: Gene Regulation Laboratories            Topic: N/A

    DESCRIPTION (provided by applicant): The beta thalassemia syndromes are prevalent genetic disorders caused by molecular mutations affecting the genes for adult hemoglobin and cause early mortality from complications of blood transfusions. These conditions can be ameliorated by reactivating production of fetal hemoglobin (Hb F) in the patients' blood. Pharmacologic re-induction of HbF has been achi ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Osteopontin, a Novel Neuroprotectant in Brain Ischemia

    SBC: VIROGENOMICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This is an STTR Phase II proposal to develop the application of a novel neuroprotectant in the treatment of stroke. As in our previous Phase I STTR, this Phase II STTR unites the Stenzel-Poore laboratory and Virogenomics, Inc., a Portland-based genomics and drug discovery company. Here we plan to develop the use of an endogenous 'injury response' protein, osteo ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  8. CODA Assembly of Mutant Genes

    SBC: CODA GENOMICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The opportunity addressed by this proposal is to provide the scientific and medical communities with the ability to perform rapid, inexpensive, and accurate mutation studies of any protein, using a scaffold based on synthetic genes computationally optimized for DNA self assembly and for expression and translation in an in vitro or in vivo system of choice. Cu ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  9. HLA-DR4-derived RTLs for Treating Rheumatoid Arthritis

    SBC: VIROGENOMICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The specific goal of this Phase I STTR is to design, manufacture, characterize and evaluate a set of therapeutic agents that can control the pathogenic CD4+ T cells that mediate an inflammatory autoimmune disease, rheumatoid arthritis (RA). The approach presented is based on patented Recombinant T cell receptor Ligand (RTL) technology (US Patent # 6,270,772) fo ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Integrated Biochip for In-Vitro Toxicology

    SBC: Solidus Biosciences, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Solidus Biosciences, Inc. is developing a proprietary Metabolizing Enzyme Toxicology Assay Chip (MetaChip), along with a xenobiotic metabolism and toxicity screening device that uses these chips (the MetaReader), for high- throughput analysis of drug metabolism and toxicity. The MetaChip integrates the high-throughput metabolite- generating capability of P450 c ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government